Australia, June 4 -- CRISPR Therapeutics AG, owns the trademark (2638403) for 'CTX460' till March 24, 2036.
Status: registered:
Registered/protected
Classes: 5 [Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of lung and liver diseases or conditions; pharmaceutical and biopharmaceutical agents for the treatment of lung and liver diseases or conditions in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of lung and liver diseases or conditions in the field of in vivo gene editing therapy] and 42 [Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy]
Type of Mark: Word
Date of Acceptance: March 26
Registration Advertised: June 3
For further details contact Griffith Hack.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2638403.
Disclaimer: Curated by HT Syndication.
